<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03156777</url>
  </required_header>
  <id_info>
    <org_study_id>XH-16-038</org_study_id>
    <nct_id>NCT03156777</nct_id>
  </id_info>
  <brief_title>Application Value of CTCs Detection for Advanced Gastric Cancer Patients</brief_title>
  <official_title>A Single Center Observational Study to Evaluate the Application Value of Circulating Tumor Cell Detection for Advanced Gastric Cancer Patients in Prediction of the Prognosis and Evaluation of the Outcome of Adjuvant Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xinhua Hospital, Shanghai Jiao Tong University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Xinhua Hospital, Shanghai Jiao Tong University School of Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluating the application value of a new circulating tumor cell detection method for
      advanced gastric cancer patients in prediction of the prognosis and early evaluation of the
      result of postoperation adjuvant chemotherapy.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>3 Years</target_duration>
  <primary_outcome>
    <measure>Number of circulating tumor cell (CTC)</measure>
    <time_frame>Up to 2 years from start of study</time_frame>
    <description>Number of the circulating tumor cell in peripheral blood from advanced gastric cancer patients undergoing D2 radical resection followed by first-line chemotherapy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Profile and Portion of circulating tumor cell (CTC)</measure>
    <time_frame>Up to 2 years from start of study</time_frame>
    <description>Profile and Portion of the circulating tumor cell in peripheral blood from advanced gastric cancer patients undergoing D2 radical resection followed by first-line chemotherapy. There are three type of CTCs: epithelial type CTCï¼Œmesenchymal type CTC and mixed type CTC. The portion of different type of CTC were calculated, for example: the portion of epithelia type CTC number to total CTCs,etc.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>Up to 3 years from start of the study</time_frame>
    <description>Survival duration since radical resection to clinical finding of relapse disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Up to 5 years from start of the study</time_frame>
    <description>Survival duration since radical resection to patient die.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Circulating Tumor Cells</condition>
  <condition>Gastric Cancer</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Advanced gastric cancer patients
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Subjects eligible for enrollment must meet all of the following criteria:

          1. Provide signed informed consent. The subject is capable of understanding and complying
             with parameters as outlined in the protocol and able to sign informed consent,
             approved by the Independent Ethic Committee (IEC)/Institutional Review Board (IRB)
             prior to the initiation of any study-specific procedures

          2. Men or women aged &gt;= 18 years and &lt;=75 years.

          3. Eastern Cooperative Oncology Group Performance Status (ECOG) &lt;= 2.

          4. Histologically confirmed adenocarcinoma of the stomach, gastroesophageal junction.

          5. Metastatic disease or locally advanced disease not amenable to curative surgery.

          6. Radiographically assessable, non-measurable disease or measurable disease as per
             RECIST criteria.

          7. Life expectancy of at least 12 weeks with tumor and at least 5 years without tumor
             from the time of enrollment.

          8. No other malignancy within the past 5 years except adequately treated basal cell or
             squamous cell skin cancer or carcinoma in situ of the cervix.

          9. No prior chemotherapy for advanced disease. -

        Exclusion Criteria:

        Subjects meeting any of the following criteria must not be enrolled in the study:

          1. Gastric carcinoid, sarcomas, or squamous cell cancer.

          2. Pregnant or lactating females.

          3. Significant neurological or psychiatric disorders (psychotic disorders, dementia or
             seizures) that would prohibit the understanding and giving of informed consent.

          4. Active Hepatitis B or C or history of an HIV infection.

          5. Active uncontrolled infection. -
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wei Lu, M.D. &amp; Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Xinhua Hospital, Shanghai Jiao Tong University School of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yinbing Liu, M.D. &amp; Ph.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Xinhua Hospital, Shanghai Jiao Tong University School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xin Zhou, M.D. &amp; Ph.D.</last_name>
    <phone>+862125078999</phone>
    <email>xinhuacru@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Beiqing Jiang</last_name>
    <phone>+862125078922</phone>
    <email>xinhuakeyan@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Xinhua Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200092</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Beiqing Jiang</last_name>
      <phone>+862125078922</phone>
      <email>xinhuakeyan@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 30, 2016</study_first_submitted>
  <study_first_submitted_qc>May 15, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 17, 2017</study_first_posted>
  <last_update_submitted>May 15, 2017</last_update_submitted>
  <last_update_submitted_qc>May 15, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Gastric cancer; Circulating tumor cells; Prognosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
    <mesh_term>Neoplastic Cells, Circulating</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

